Inclusion on the list “en sus”: the importance of the place in the therapeutic strategy
As a reminder, only products whose added expected benefit (ASA, for medical devices) or added medical benefit (ASMR, for pharmaceutical…
LFSS 2025: When will the pharmaceutical products new measures be applicable?
In its decision no. 2025-875 DC issued on Friday, the Constitutional Council ruled on the conformity with the Constitution of the…
LFSS 2025: When will the medical devices new measures be applicable?
In its decision no. 2025-875 DC issued on Friday, the Constitutional Council ruled on the conformity with the Constitution of the…
Does the failure to produce the studies requested by the HAS justify the withdrawal of reimbursement for the product?
When assessing the medical benefit (SMR) and the expected benefit (SA) of a healthcare product, the French Transparency Commission (CT)…
What can we learn from the 2025 expenses and income report?
Article L. 111-11 of the French Social Security Code stipulates that the Union nationale des caisses d'assurance maladie (French National Union…
Requesting a price that is “too high” may justify the refusal of reimbursement… without negotiation!
The French Social Security Code allows ministers to refuse the reimbursement of a healthcare product if it is likely to…